Telehealth Affiliate Marketing Compliance Guide

Current updates and key dates

Checked November 14, 2026. This is a selected update log, not a complete legal tracker. Recheck official sources before each launch or material campaign change.

Disclose affiliate and sponsor relationships

The FTC Endorsement Guides explain when material connections must be disclosed. Make compensation clear where people encounter the recommendation, before they act. Do not rely only on a footer, profile page or hidden video description.

• Adapt the disclosure to the actual relationship: a paid sponsorship, free service or commission are different arrangements.
• For video, make disclosures noticeable in the video; do not rely only on its description. Match disclosure format to the endorsement.
• Explain truthfully whether compensation affects comparison rankings or inclusion. Do not claim independence or unchanged pricing without support.

Health claims need evidence

FTC Health Products Compliance Guidance explains that health and safety claims need competent and reliable scientific support. Review the overall impression of headlines, images, testimonials and omissions. A disclaimer cannot contradict the main message.

• Use substantiated wording approved for the specific program; advertiser approval alone is not evidence.
• Do not promise guaranteed eligibility, prescriptions, outcomes or risk-free treatment.
• Keep drug approval, provider licensing and pharmacy registration distinct. None implies approval of an entire telehealth business.
• Show material price limitations and required fees clearly. Do not call an intake or consultation free if unavoidable charges contradict that impression.

MarketHealth campaign restrictions can be stricter than general law. Follow the offer brief's limits on results, timelines, creative and traffic sources.

Reviews, testimonials and before-and-after content

The FTC reviews rule prohibits fake experiences, sentiment-conditioned review incentives and deceptive claims of independence by controlled review sites. Do not present AI personas, stock photos or actors as actual customers.

• Testimonials must reflect genuine experience. Disclose compensation or other material connections.
• Do not condition incentives on positive sentiment or use prohibited review-suppression practices.
• Before-and-after images must be genuine, authorized and not misleadingly edited. Under FTC endorsement guidance, atypical results need clear disclosure of substantiated generally expected performance; “results vary” alone is insufficient.
• MarketHealth requires advertiser review of testimonial and progress-photo creative before use.

GLP-1 marketing and compounding

FDA's March 2026 warning-letter announcement addresses misleading sameness claims and branding that obscures the compounder. Compounded drugs are not FDA-approved generics. Do not imply equivalence to an approved brand or misidentify who compounded a product.

• Check FDA's compounding policy clarification. Shortage-era allowances are not permanent permission. Rules differ for 503A patient-specific compounding and 503B outsourcing; a prescription or added vitamin is not automatic clearance.
• FDA states retatrutide and cagrilintide cannot be used in compounding under federal law. Do not promote them as available compounded treatments.
• Review current product labeling and FDA's November 9, 2026 safety communication. Have the advertiser refresh relevant risk language; do not improvise clinical advice.
• MarketHealth prohibits weight-loss guarantees and unapproved numerical results or timelines. A clinician determines whether treatment is appropriate.

See the GLP-1 category page.

TRT and controlled-medication prescribing

Testosterone is a Schedule III controlled substance. The DEA/HHS fourth temporary extension runs through December 31, 2026. It permits qualifying remote prescribing without a prior in-person evaluation under specified conditions, including federal and state requirements; it does not eliminate clinical evaluation or licensing.

• Do not promise remote-only prescribing without verifying the actual program and prescribing pathway.
• Check published DEA/HHS rules before promoting care extending into 2027. A proposal or extension request is not an adopted rule.
• MarketHealth campaign rules prohibit bodybuilding, performance and anti-aging promises or physique before-and-after promotions. Lead with clinician evaluation.

See the TRT category page.

HRT and menopause

The February 12, 2026 FDA announcement changed specific boxed-warning risk statements for six products. It did not remove every warning or make all hormone therapy risk-free. Confirm the current label for the exact product; do not extend the changes to compounded hormones.

• Present treatment decisions as individual clinician decisions, not universal recommendations.
• Do not claim compounded or “bioidentical” products are inherently safer or more effective.
• Use the advertiser's substantiated, product-specific wording and relevant risk information.

See the HRT category page.

Peptides: conditional policy is not FDA approval

The October 30 Federal Register notice published an HHS draft for comment; its announced November 13 deadline has passed. Closing comments does not finalize a bulks-list rule or approve drugs.

The published HHS policy and appendices describe conditional federal non-enforcement for specified identities and routes involving BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Conditions include ingredient sourcing, testing, reporting, labeling and single-active-ingredient requirements. Do not extrapolate to every peptide, route, blend or research supplier.

• Verify product-specific eligibility, current policy and state requirements with the program's qualified professionals. A licensed prescriber and pharmacy alone do not prove every formulation is lawful.
• MarketHealth telehealth campaigns must not direct consumers to research-use-only products for human treatment.
• No unsupported recovery, healing, anti-aging or performance promises, and no dosing, stacks or reconstitution instructions in affiliate promotions.

See the peptides category page.

Other categories, pricing and subscriptions

• ED and sexual health: no guaranteed prescription or unsubstantiated performance claims; follow the brief's creative restrictions.
• Women's health: do not select a treatment for a reader or substitute affiliate advice for clinical assessment.
• Dermatology: distinguish cosmetic products from prescription treatment; progress photos remain advertising claims.

Make recurring charges clear

For online negative-option offers, ROSCA requires material terms before obtaining billing information, express informed consent before charging, and a simple way to stop recurring charges. Explain required membership, medication, consultation and shipping charges, renewal amounts and cancellation steps accurately. State laws may add requirements.

The FTC's vacated 2024 “click-to-cancel” amendment should not be presented as an operative nationwide requirement. See the FTC's 2026 rule revision; other applicable consumer-protection obligations remain.

Referral compensation and category boundaries

HHS OIG explains that the federal Anti-Kickback Statute addresses knowing and willful remuneration inducing or rewarding business payable by federal healthcare programs. EKRA (18 USC 220) separately addresses referrals involving recovery homes, clinical treatment facilities and laboratories, subject to its terms and exceptions.

MarketHealth campaign boundaries: cash-pay programs only; no affiliate payouts on insurance-billed services. Lab/testing programs require legal review. Existing excluded categories include addiction treatment, controlled-substance psychiatry, medication abortion and research-use-only products. These marketplace restrictions do not certify any other arrangement as lawful.

Privacy and tracking

The Hims & Hers lawsuit remains pending. Its privacy allegations reinforce the need to verify data flows. FTC guidance explains that inferred health interests and browsing or purchase information can also be sensitive; HIPAA is not the only potentially relevant framework.

• MarketHealth's baseline is minimal server-to-server attribution. Do not include conditions, medications, intake answers or patient details in links, sub-IDs, pixels or postbacks.
• Click IDs, order IDs, event names and hashed emails are not automatically anonymous. Review whether they can identify a person or reveal treatment or health interests.
• Server-to-server transmission is not a compliance guarantee. Review data recipients, purpose, access and retention; do not treat a generic cookie banner as universal authorization.
• Assess HIPAA where applicable, FTC Act obligations, the Health Breach Notification Rule where applicable, and relevant state privacy laws. Do not upload health-based audiences to ad platforms without a specifically reviewed lawful basis.

Email and SMS

MarketHealth telehealth email campaigns use approved opt-in audiences. CAN-SPAM also requires accurate sender and subject information, a postal address, a working opt-out and timely suppression. SMS remains prohibited unless the offer brief permits it; permission in a brief does not replace applicable consent and communications-law requirements.

Paid-platform approvals

Google's healthcare policy requires certification for restricted prescription-drug services; U.S. telemedicine promotion requires LegitScript healthcare certification and Google certification. Google's application guidance covers account, domain, service and location requirements and documentation for agency relationships.

Do not assume a provider's approval covers an affiliate's separate account, domain or landing page. Verify the actual setup. Other platforms have their own eligibility and authorization requirements; approval on one platform is not transferable permission.

MarketHealth rules: paid search and paid social require approval; brand bidding is prohibited unless the brief allows it. Do not launch while eligibility is unresolved. See telehealth ad platform rules and recheck the platform's current source policy.

Pre-launch publisher checklist

• 01Disclosure matches the actual financial relationship and is easy to notice.
• 02Health, pricing and eligibility claims are substantiated and match the brief.
• 03Drug status and compounder identity are accurate; no approval or equivalence implications.
• 04Testimonials are genuine and expected-results disclosures are supported.
• 05Required charges, renewals and cancellation terms match the actual funnel.
• 06Referral compensation and eligible markets have arrangement-specific legal review.
• 07Tracking identifiers, events and recipients have privacy review.
• 08Accounts, domains, traffic sources and creative have the required approvals.
• 09Source dates, product labels and prescribing rules are current.

Official sources

Sources checked November 14, 2026. This educational guide is not legal or medical advice or a certification of a program's compliance. Qualified counsel should review the specific campaign and compensation arrangement.

• Federal Register: peptide draft notice and comment window
• HHS: peptide policy and appendices
• FTC: Hims & Hers case docket
• FDA: November 9, 2026 GLP-1 safety communication
• DEA: fourth temporary extension
• FDA: March 2026 telehealth warning letters
• FDA: GLP-1 compounding policy update
• FDA: unapproved GLP-1 concerns
• FDA: February 2026 hormone labeling changes
• FTC: Endorsement Guides Q&A
• FTC: Health Products Compliance Guidance
• FTC: fake reviews and testimonials rule
• FTC: ROSCA
• FTC: 2026 Negative Option Rule revision
• HHS OIG: fraud and abuse laws
• U.S. Code: EKRA
• Florida Legislature: patient brokering
• FTC: consumer health information guidance
• FTC: CAN-SPAM guide
• Google: healthcare and medicines
• Google: prescription-drug services